CA2816423A1 - Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders - Google Patents
Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders Download PDFInfo
- Publication number
- CA2816423A1 CA2816423A1 CA2816423A CA2816423A CA2816423A1 CA 2816423 A1 CA2816423 A1 CA 2816423A1 CA 2816423 A CA2816423 A CA 2816423A CA 2816423 A CA2816423 A CA 2816423A CA 2816423 A1 CA2816423 A1 CA 2816423A1
- Authority
- CA
- Canada
- Prior art keywords
- ic3b
- lateral flow
- complement
- flow immunoassay
- intact
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003018 immunoassay Methods 0.000 title claims abstract description 122
- 230000024203 complement activation Effects 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 78
- 230000000295 complement effect Effects 0.000 title claims abstract description 68
- 238000011282 treatment Methods 0.000 claims abstract description 41
- 210000001124 body fluid Anatomy 0.000 claims abstract description 39
- 239000010839 body fluid Substances 0.000 claims abstract description 39
- 108010078015 Complement C3b Proteins 0.000 claims description 181
- 238000012360 testing method Methods 0.000 claims description 94
- 208000014674 injury Diseases 0.000 claims description 58
- 102100022133 Complement C3 Human genes 0.000 claims description 54
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 230000004913 activation Effects 0.000 claims description 40
- 230000002757 inflammatory effect Effects 0.000 claims description 38
- 208000027418 Wounds and injury Diseases 0.000 claims description 37
- 239000012528 membrane Substances 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 208000035475 disorder Diseases 0.000 claims description 32
- 239000012491 analyte Substances 0.000 claims description 31
- 230000009429 distress Effects 0.000 claims description 25
- 239000003550 marker Substances 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 22
- 230000008733 trauma Effects 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 12
- 102000000989 Complement System Proteins Human genes 0.000 claims description 12
- 108010069112 Complement System Proteins Proteins 0.000 claims description 12
- 206010035664 Pneumonia Diseases 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 11
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 11
- 206010040047 Sepsis Diseases 0.000 claims description 10
- 206010052428 Wound Diseases 0.000 claims description 10
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 210000002381 plasma Anatomy 0.000 claims description 9
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 210000000416 exudates and transudate Anatomy 0.000 claims description 8
- 210000001138 tear Anatomy 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 239000004074 complement inhibitor Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 108010052926 complement C3d,g Proteins 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 5
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000035935 pregnancy Effects 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- 229940044551 receptor antagonist Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010049119 Emotional distress Diseases 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 201000001505 hemoglobinuria Diseases 0.000 claims description 3
- 230000001314 paroxysmal effect Effects 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims description 2
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 claims description 2
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 claims description 2
- 101150073986 C3AR1 gene Proteins 0.000 claims description 2
- 206010053159 Organ failure Diseases 0.000 claims description 2
- 108010027437 compstatin Proteins 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 81
- 238000003556 assay Methods 0.000 description 66
- 230000006378 damage Effects 0.000 description 32
- 230000037361 pathway Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 12
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 10
- 230000004064 dysfunction Effects 0.000 description 9
- 206010038687 Respiratory distress Diseases 0.000 description 8
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000028709 inflammatory response Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000034486 Multi-organ failure Diseases 0.000 description 7
- 208000010718 Multiple Organ Failure Diseases 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000012723 sample buffer Substances 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- 102100031506 Complement C5 Human genes 0.000 description 5
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 5
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 5
- 108090001090 Lectins Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000004154 complement system Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 4
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 4
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 4
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010028780 Complement C3 Proteins 0.000 description 3
- 108090000056 Complement factor B Proteins 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000010398 acute inflammatory response Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000009528 severe injury Effects 0.000 description 3
- 208000037974 severe injury Diseases 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 102000016550 Complement Factor H Human genes 0.000 description 2
- 108010053085 Complement Factor H Proteins 0.000 description 2
- 102000003689 Complement Factor I Human genes 0.000 description 2
- 108090000044 Complement Factor I Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000004221 Multiple Trauma Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000021917 activation of membrane attack complex Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 208000006893 Fetal Hypoxia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 101100006979 Rattus norvegicus C4 gene Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000009158 Traumatic Intracranial Hemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000002388 complement deficiency Diseases 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000005001 laminate film Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40929710P | 2010-11-02 | 2010-11-02 | |
| US61/409,297 | 2010-11-02 | ||
| PCT/US2011/058945 WO2012071145A1 (en) | 2010-11-02 | 2011-11-02 | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2816423A1 true CA2816423A1 (en) | 2012-05-31 |
Family
ID=46146161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2816423A Abandoned CA2816423A1 (en) | 2010-11-02 | 2011-11-02 | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9182396B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2635702B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5859557B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2011332241B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2816423A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2564290T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX340094B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012071145A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5859557B2 (ja) * | 2010-11-02 | 2016-02-10 | カイファ， インコーポレイテッド | 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法 |
| US8865164B2 (en) * | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| WO2014005138A1 (en) * | 2012-06-29 | 2014-01-03 | Kerschensteiner Daniel A | Colorimetric gelatinase assay |
| CN105283761B (zh) * | 2013-06-10 | 2018-02-09 | 旭化成株式会社 | 免疫层析诊断试剂盒 |
| CN106461661A (zh) | 2014-05-02 | 2017-02-22 | Uab研究基金会 | 用于诊断和治疗脑膜炎的方法及组合物 |
| WO2017040243A1 (en) * | 2015-08-28 | 2017-03-09 | Kypha, Inc. | Methods for predicting flare and improving treatment of patients |
| KR102141591B1 (ko) * | 2016-05-13 | 2020-09-14 | 광주과학기술원 | 진단용 키트 |
| EP3775900A1 (en) * | 2018-03-26 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | High throughput method for measuring the protease activity of complement c3 convertase |
| EP3581934A1 (en) * | 2018-06-14 | 2019-12-18 | Otto-von-Guericke-Universität Magdeburg | Complement factors for diagnosis of low-grade infections in a human subject |
| WO2021222169A1 (en) * | 2020-04-27 | 2021-11-04 | Zinselmeyer Bernd H | Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2 |
| WO2022067259A1 (en) * | 2020-09-28 | 2022-03-31 | Allegheny Singer Research Institute | Methods for determining a level of a cell fragment-bound complement activation product |
| US20240302366A1 (en) * | 2021-01-26 | 2024-09-12 | Sekisui Medical Co., Ltd. | Immunological assay method |
| EP4334719A4 (en) * | 2021-05-07 | 2025-04-16 | Kypha, Inc. | TARGET MEASUREMENT |
| WO2023192436A1 (en) * | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
| JPS595958B2 (ja) | 1975-12-30 | 1984-02-08 | トウキヨウケイソウ カブシキガイシヤ | 変量測定・伝送装置 |
| DE3366421D1 (en) * | 1982-06-14 | 1986-10-30 | Upjohn Co | Method and kit for removing and assaying complement system fragments |
| SE452067B (sv) | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Reagens for och sett vid immunkemisk bestemning av c3a |
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| IL89790A (en) | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
| US7371582B2 (en) * | 2002-01-23 | 2008-05-13 | Boditechmed Inc. | Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor |
| WO2004093636A2 (en) * | 2003-04-17 | 2004-11-04 | Rauno Joks | PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY |
| KR20060015646A (ko) | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | 면역, 혈액 및 염증성 질환의 모니터링 방법 |
| US20070224703A1 (en) | 2003-09-29 | 2007-09-27 | Fariba Nayeri | Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids |
| WO2005078442A1 (en) | 2004-02-10 | 2005-08-25 | Dantini Daniel C | Comprehensive food allergy test |
| US20060292700A1 (en) * | 2005-06-22 | 2006-12-28 | Naishu Wang | Diffused interrupted lateral flow immunoassay device and method |
| WO2006124888A2 (en) * | 2005-05-16 | 2006-11-23 | Brendan Bioscience, Llc | Detection of antigen specific immunocomplexes |
| US7910381B2 (en) | 2005-10-13 | 2011-03-22 | BioAssay Works | Immuno gold lateral flow assay |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| EP2313527A4 (en) * | 2008-07-15 | 2012-11-21 | Rapid Pathogen Screening Inc | Lateral flow NUCLEIC DETECTOR |
| WO2010077722A1 (en) * | 2008-12-30 | 2010-07-08 | Centocor Ortho Biotech Inc. | Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis |
| WO2010135717A2 (en) * | 2009-05-21 | 2010-11-25 | Potentia Pharmaceuticals, Inc. | Complement assays and uses thereof |
| JP5859557B2 (ja) | 2010-11-02 | 2016-02-10 | カイファ， インコーポレイテッド | 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法 |
| US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
-
2011
- 2011-11-02 JP JP2013537784A patent/JP5859557B2/ja active Active
- 2011-11-02 EP EP11842681.6A patent/EP2635702B1/en active Active
- 2011-11-02 US US13/287,432 patent/US9182396B2/en active Active
- 2011-11-02 ES ES11842681.6T patent/ES2564290T3/es active Active
- 2011-11-02 EP EP15199549.5A patent/EP3095876A1/en not_active Withdrawn
- 2011-11-02 MX MX2013004960A patent/MX340094B/es active IP Right Grant
- 2011-11-02 WO PCT/US2011/058945 patent/WO2012071145A1/en not_active Ceased
- 2011-11-02 AU AU2011332241A patent/AU2011332241B2/en active Active
- 2011-11-02 CA CA2816423A patent/CA2816423A1/en not_active Abandoned
-
2015
- 2015-08-13 US US14/825,437 patent/US9939446B2/en active Active
-
2016
- 2016-02-05 AU AU2016200772A patent/AU2016200772B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013004960A (es) | 2013-12-16 |
| AU2016200772A1 (en) | 2016-02-25 |
| AU2011332241A1 (en) | 2013-05-23 |
| ES2564290T3 (es) | 2016-03-21 |
| AU2011332241A2 (en) | 2013-06-13 |
| MX340094B (es) | 2016-06-27 |
| US9939446B2 (en) | 2018-04-10 |
| AU2016200772B2 (en) | 2018-02-01 |
| US20120141457A1 (en) | 2012-06-07 |
| EP3095876A1 (en) | 2016-11-23 |
| JP2014502347A (ja) | 2014-01-30 |
| EP2635702A1 (en) | 2013-09-11 |
| JP5859557B2 (ja) | 2016-02-10 |
| US20150346211A1 (en) | 2015-12-03 |
| EP2635702A4 (en) | 2014-04-02 |
| US9182396B2 (en) | 2015-11-10 |
| AU2011332241B2 (en) | 2015-11-26 |
| EP2635702B1 (en) | 2016-02-03 |
| WO2012071145A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2635702B1 (en) | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders | |
| US9164088B2 (en) | Detecting complement activation | |
| CA3084064A1 (en) | Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury | |
| CN110709704A (zh) | 利用心肌肌钙蛋白i辅助诊断和评估人类受试者的轻度创伤性脑损伤的方法 | |
| AU2013256496B2 (en) | Detecting complement activation | |
| US10830774B2 (en) | Methods and compositions for diagnosis and treatment of meningitis | |
| JP7454945B2 (ja) | 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法 | |
| CN111094981A (zh) | Pct和pro-adm作为监测抗生素治疗的标记物 | |
| HK1208267B (en) | Detecting complement activation | |
| WO2010085568A1 (en) | Methods of diagnosing and treating severe dry eye syndrome | |
| KR20180121057A (ko) | Aimp1을 포함하는 전신 홍반성 루프스 진단용 바이오마커 조성물 및 이를 이용한 전신 홍반성 루프스 진단 방법 | |
| HK1234826B (en) | Methods and compositions for diagnosis and treatment of meningitis | |
| HK1234826A1 (en) | Methods and compositions for diagnosis and treatment of meningitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161031 |
|
| FZDE | Discontinued |
Effective date: 20200831 |